- Home
- PROK vs MYPS Comparison
PROK vs MYPS Comparison
Compare PROK & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- MYPS
- Stock Information
- Founded
- PROK 2015
- MYPS 2011
- Country
- PROK United States
- MYPS United States
- Employees
- PROK N/A
- MYPS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- MYPS EDP Services
- Sector
- PROK Health Care
- MYPS Technology
- Exchange
- PROK Nasdaq
- MYPS Nasdaq
- Market Cap
- PROK 206.0M
- MYPS 218.2M
- IPO Year
- PROK N/A
- MYPS N/A
- Fundamental
- Price
- PROK $1.50
- MYPS $1.70
- Analyst Decision
- PROK Buy
- MYPS Hold
- Analyst Count
- PROK 5
- MYPS 5
- Target Price
- PROK $4.50
- MYPS $3.17
- AVG Volume (30 Days)
- PROK 344.0K
- MYPS 121.0K
- Earning Date
- PROK 03-21-2025
- MYPS 03-10-2025
- Dividend Yield
- PROK N/A
- MYPS N/A
- EPS Growth
- PROK N/A
- MYPS N/A
- EPS
- PROK N/A
- MYPS N/A
- Revenue
- PROK N/A
- MYPS $298,759,000.00
- Revenue This Year
- PROK N/A
- MYPS N/A
- Revenue Next Year
- PROK N/A
- MYPS N/A
- P/E Ratio
- PROK N/A
- MYPS N/A
- Revenue Growth
- PROK N/A
- MYPS N/A
- 52 Week Low
- PROK $1.34
- MYPS $1.20
- 52 Week High
- PROK $4.44
- MYPS $3.04
- Technical
- Relative Strength Index (RSI)
- PROK 41.47
- MYPS 42.95
- Support Level
- PROK $1.50
- MYPS $1.69
- Resistance Level
- PROK $1.67
- MYPS $1.90
- Average True Range (ATR)
- PROK 0.10
- MYPS 0.10
- MACD
- PROK -0.00
- MYPS 0.00
- Stochastic Oscillator
- PROK 10.71
- MYPS 31.03
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore, and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.